Home / Letter From The Editor (page 96)

Letter From The Editor

Editor’s Note, DCMS #148

The most severe potential complication of DKA management is cerebral edema. It accounts for 60 – 90% of all DKA deaths. So if a newly diagnosed or young patient starts to slip into DKA, the proper treatment is very, very important. In addition, diagnosing cerebral edema is hard especially in …

Read More »

Letter from the Editor, #688

Over and over we have new therapies for diabetes come to the market with lots of promise and hope. These new classes with great results in pre-marketing studies offer extra armament to fight the epidemic of diabetes yet they don’t get used because of words like "cardiac arrest" and "cancer." …

Read More »

Editor’s Note, DCMS #147

I just finished a program in Danville, California, on hospital readmissions where I spoke to medical professionals about the high cost of readmissions and possible ways to avoid them. The program focused on using care and case managers to properly help patients leave the hospital, avoiding costly and sometimes deadly …

Read More »

Special Edition, SGLT2-Inhibitors, Editor’s Desk

We have now had about three months of use of the new medication, Invokana (canagliflozin). During this time many publications including our own newsletter have been running feature stories as well as ads for the product. This delivery of information is in addition to the field representatives calling on prescribers. …

Read More »

Editor’s Note, DCMS #145:

If you look at the notes from the AACE conference, the AAFP conference and the recent ADA Scientific Sessions, you’ll notice a lot of new algorithms for the treatment of diabetes. All this information reminds me of when I was working on improving my golf game. First they told me …

Read More »